Table 1:

Neuroimaging parameters of the included studies

Studies	Scanner/Technique/Field Strength	Gap/Raters
Benedictus et al, 2013²⁸	GE Healthcare/EPI/3T	Unknown/1 neuroradiologist
Cordonnier et al, 2006⁷	Siemens/GRE/1T	1.5/1 observer, type unknown
Fukui et al, 2013^{21,^a}	Unknown/GRE/1.5T	Unknown
Goos et al, 2011^{22,^b}	Siemens/GRE/1.5	1.5/1 rater, type unknown
	Siemens/SWI/1.5T	NA/1 rater, type unknown
Kester et al, 2014^{29,^a}	GE Healthcare, Siemens/GRE/1T, 1.5T, and 3T	Unknown
Kirsch et al, 2009⁴	Siemens/SWI/1.5T	NA/4 readers +1 neuroradiologist
Nagasawa et al, 2014²⁰	Unknown/GRE/1.5T	0.5/2 neurologists, 1 neuroradiologist
Nagata et al, 2012⁴⁰	Unknown/EPI/1.5T	Unknown/unknown
Nakata-Kudo et al, 2006⁴¹	Philips/GRE/1.5T	1/1 neurologist, 1 radiologist
Park et al, 2013⁴²	Philips/GRE/3T	2/2 neurologists in consensus
Qiu et al, 2010⁴³	GE Healthcare/EPI/1.5T	NA/1 neuroradiologist and subsequent raters
Staekenborg et al, 2009⁴⁴	Siemens/GRE/1T	1.5/unknown
Uetani et al, 2013²⁴	Siemens/SWI/3T	NA/2 neuroradiologists in consensus
van der Vlies et al, 2012⁴⁵	Siemens/GRE/1T or 1.5T	1/unknown
Yates et al, 2014⁴⁶	Siemens/SWI/3T	NA/2 neuroradiologists in consensus
Zonnefeld et al, 2014⁴⁷	GE Healthcare/SWI/3T	NA/1 of 2 neuroradiologists
Postupdate
Olazarán et al, 2014²⁷	GE Healthcare/EPI/3T	NR/neuroradiologist

Note:—NA indicates not applicable; NR, examined but not reported.
↵a Studies are excluded at the moderating factor analyses. Only the van der Vlies et al⁴⁵ 2012 study reported the percentage of medicated patients with AD.
↵b Two different techniques were used with the same cohort.